Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria ( EPP ) , Including Potential for Accelerated Approval

a week ago

WATERTOWN, Mass., Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced ...

Ticker	Sentiment	Impact
IRON	Neutral	6 %